Annual report 2022/2023
DE
DE
Home
To our Shareholders
To our Shareholders
Letter from the CEO
Report from the Supervisory Board
Composition of the Supervisory Board
Corporate Governance Declaration
Corporate Governance Declaration
Statement of conformity by the Management and Supervisory boards of BRAIN Biotech AG with the recommendations of the German Corporate Governance Code (DCGK) pursuant to Section 161 (1) Sentence 1 of the German Stock Corporation Act (AktG)
Relevant information about corporate governance practices
Company
Company
BRAIN Biotech at a Glance
Important Events
Why invest in BRAIN Biotech?
The BRAIN Biotech Share and the Capital Market
The BRAIN Biotech Share and the Capital Market
Capital market environment
The BRAIN Biotech Share
Group Management Report
Group Management Report
Basis of the Group
Economic and Business Report
Economic and Business Report
Macroeconomic and sector-related conditions
Business progress
Results of operations
Net assets and financial position
Employees
Overall statement on business progress
Events after the reporting date
Outlook
Report on Risks and Opportunities
Report on Risks and Opportunities
1 Risk management at BRAIN Biotech AG
2 Report on Risks and Opportunities
3 Assessment of opportunities and risks in overall presentation
4 Report on opportunities
Takeover-relevant Information pursuant to Section 315a of the German Commercial Code (HGB)
Corporate Governance Statement of Conformity pursuant to Section 289f and Section 315d of the German Commercial Code (HGB)
Consolidated Financial Statements
Consolidated Financial Statements
Consolidated Balance Sheet
Consolidated Statement of comprehensive Income
Consolidated Statement of Changes in Equity
Consolidated Statement of Cash Flows
Notes to the consolidated Financial Statements
Notes to the consolidated Financial Statements
I. General information
II. Basis of the consolidated financial statements
III. Accounting policies
IV. Segment reporting
V. Notes to the consolidated statement of comprehensive income
VI. Notes to the consolidated balance sheet
VII. Financial instruments / risks from financial instruments
VIII. Other information
Responsibility statement
Independent Auditor´s Report
Services
Services
Glossary
Financial Calender
Contact
Download Center
Group Management Report
Basis of the Group
Economic and Business Report
Events after the reporting date
Outlook
Report on Risks and Opportunities
Takeover-relevant Information pursuant to Section 315a of the German Commercial Code (HGB)
Corporate Governance Statement of Conformity pursuant to Section 289f and Section 315d of the German Commercial Code (HGB)
Home
Group Management Report
Report on Risks and Opportunities
Report on Risks and Opportunities
1 Risk management at BRAIN Biotech AG
2 Report on Risks and Opportunities
3 Assessment of opportunities and risks in overall presentation
4 Report on opportunities
Top
